Advertisement
Review| Volume 45, ISSUE 3, P354-359, February 2009

OECI Workshop on late side-effects of cancer treatments

Published:December 10, 2008DOI:https://doi.org/10.1016/j.ejca.2008.10.005

      Abstract

      This Workshop was organised by the Organisation of European Cancer Institutes (OECI) to provide a forum for discussing the late side-effects resulting from different cancer treatments. One of the main Workshop objectives was to generate recommendations on how to improve knowledge and, consequently, long-term care for cancer survivors.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Coleman M.P.
        • Quaresma M.
        • Berrino F.
        • et al.
        Cancer survival in five continents: a worlwide population-based study (CONCORD).
        Lancet Oncol. 2008; 9: 730-756
        • Fosså S.D.
        Long-term sequelae after cancer therapy. Survivorship after treatment for testicular cancer.
        Acta Oncologica. 2004; 43: 134-141
        • Fosså S.D.
        • Gilbert E.
        • Dores G.M.
        • et al.
        Noncancer causes of death in survivors of testicular cancer.
        J Natl Cancer Inst. 2007; 99: 533-544
        • Travis L.B.
        • Fosså S.D.
        • Schonfeld S.J.
        • et al.
        Second cancers among 40, 576 testicular cancer patients: focus on long-term survivors.
        J Natl Cancer Inst. 2005; 97: 1354-1365
        • van den Belt-Dusebout A.W.
        • de Wit R.
        • Gietema J.A.
        • et al.
        Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer.
        J Clin Oncol. 2007; 25: 4341-4343
        • Franklin J.
        • Pluetschow A.
        • Paus M.
        • et al.
        Second malignancy risk associated with treatment of Hodgkin´s lymphoma: meta-analysis of randomised trials.
        Ann Oncol. 2006; 17: 1749-1760
        • Dores G.M.
        • Metayer C.
        • Curtis R.E.
        • et al.
        Second malignant neoplasms among long-term survivors of Hodgkin’s disease: a population-based evaluation over 25 years.
        J Clin Oncol. 2002; 20: 3484-3494
        • Travis L.B.
        • Dores G.M.
        • Gospodarowicz M.
        • et al.
        Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease.
        JAMA. 2003; 290: 465-475
        • Fornander T.
        • Rutqvist L.E.
        Adjuvant tamoxifen and second cancers.
        Lancet. 1989; 8638: 616
        • Aleman B.M.
        • van den Belt-Dusebout A.W.
        • De Bruin M.L.
        • et al.
        Late cardiotoxicity after treatment for Hodgkin lymphoma.
        Blood. 2007; 109: 1878-1886
      1. Early Breast Cancer Trialists’Collaborative Group (EBCTCG). Effects of radiotherapy and of differences in the extent of surgery for early breast cancer in local recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;366:2087–106.

        • Hooning M.J.
        • Botma A.
        • Aleman M.P.
        • et al.
        Long-term risk of cardiovascular disease in 10-year survivors of breast cancer.
        J Natl Cancer Inst. 2007; 99: 365-375
        • Yeh E.T.H.
        • Tong A.T.
        • Lenihan D.J.
        • et al.
        Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management.
        Circulation. 2004; 109: 3122-3131
        • Dahl A.A.
        • Bremnes R.
        • Dahl O.
        • et al.
        Is the sexual function compromised in long-term testicular cancer survivors?.
        Eur Urol. 2007; 52: 1438-1447
      2. Fosså SD, Loge JH, Dahl AA. Long-term survivorship after cancer: how far we come? Ann Oncol 2008;(Suppl 5):25–9.

        • Dahl A.A.
        • Haaland C.F.
        • Mykletun A.
        • et al.
        Study of anxiety and depression in long-term survivors of testicular cancer.
        J Clin Oncol. 2005; 23: 2389-2395
        • Orre I.J.
        • Fosså S.D.
        • Murison R.
        • et al.
        Chronic fatigue in long-term survivors of testicular cancer.
        J Psychosom Res. 2008; 64: 363-371
        • Mykletun A.
        • Dahl A.A.
        • Haaland C.F.
        • et al.
        Side-effects and cancer-related stress determine quality of life in long-term survivors of testicular cancer.
        J Clin Oncol. 2005; 23: 3061-3068
        • Brenner D.J.
        • Doll R.
        • Goodhead D.T.
        • et al.
        Cancer risks attributable to low doses of ionizing radiation: Assessing what we really know.
        Proc Natl Acad Sci USA. 2003; 100: 13761-13766
        • Sachs R.K.
        • Brenner D.J.
        Solid tumor risks after high doses of ionizing radiation.
        Proc Natl Acad Sci USA. 2005; 102: 13040-13045
        • Tubiana M.
        • Aurengo A.
        • Averbeck D.
        • et al.
        The dabate on the use of linear no threshold for assessing the effects of low doses.
        J Radiol Prot. 2006; 26: 317-324
        • Tanooka H.
        Threshold dose-response in radiation carcinogenesis: an approach from chronic beta-irradiation experiments and a review of non-tumour doses.
        Int J Radiat Biol. 2001; 77: 541-551
        • Rothkamm K.
        • Löbrich M.
        Evidence of lack of DNA double-strand break repair in human celles exposed to very low x-ray doses.
        Proc Natl Acad Sci USA. 2003; 100: 5057-5062
        • Löbrich M.
        • Rief N.
        • Künne M.
        • et al.
        In vivo formation and repair of DNA double-strand breaks after computed tomography examinations.
        Proc Natl Acad Sci USA. 2005; 102: 8984-8989
        • Bishay K.
        • Orv K.
        • Olivier M.F.
        • et al.
        DNA damage-related RNA expression to assess individual sensitivity to ionizing radiation.
        Carcinogenesis. 2001; 8: 1179-1183
        • Amundson S.A.
        • Lee R.A.
        • Koch-Paiz C.A.
        • et al.
        Differential responses of stress genes to low dose-rate gamma irradiation.
        Mol Cancer Res. 2003; 1: 445-452
        • Franco N.
        • Lamartine J.
        • Frouin V.
        • et al.
        Low-dose exposure to gamma rays induces specific gene regulations in normal keratinocytes.
        Radiat Res. 2005; 163: 623-635
      3. Cardis E, Vrijheid M, Blettner M, et al. Risk of cancer after low doses of ionizing radiation: retrospective cohort study in 15 countries. BMJ 2005;331:77.

        • Darby S.
        • Hill D.
        • Auvinen A.
        • et al.
        Radon in homes and risk of lung cancer: collaborative analysis of individual data from 15 European case-control studies.
        BMJ. 2005; 330: 223-226
        • Taylor C.W.
        • Nisbet A.
        • McGale P.
        • et al.
        Cardiac exposures in breast cancer radiotherapy: 1950–1990s.
        Int J Radiat Oncol Biol Phys. 2007; 69: 1484-1495
        • Fowler J.F.
        The linear-quadratic formula and progress in fractionated radiotherapy: a review.
        Brit J Radiol. 1989; 62: 679-694
        • Strandqvist M.
        Studien über die Cumulative Wirkung der Röntgenstrahlen bei Fraktionierung, Erfahrungen aus dem Radiumhemmet an 280 Haut- und Lippencarzinomen.
        Acta Radiol. 1994; 55: 1-300
      4. Ellis F. The relationship of biological effect to dose-time fractionation factors in radiotherapy. In: Ebert M & Howards A, editors. Current topics in radiation research; 1968.

        • Ash D.V.
        Breast radiation injury litigation, RAGE Radiotherapy Action Group Exposure.
        Clin Oncol (R Coll Radiol). 1999; 11: 138-139
        • Mould R.F.
        • Swaine F.
        • Irwin S.
        Breast radiation injury litigation (letter).
        Brit J Radiol. 1999; 72: 925
        • Whelan T.
        • MacKenzie R.
        • Julian J.
        • et al.
        Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node-negative breast cancer.
        J Natl Cancer Inst. 2002; 94: 1143-1150
      5. The START Trialist’s Group. The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet 2008;371:1098–107.

        • Bartelink H.
        • Arriagada R.
        Hypofractionation in radiotherapy for breast cancer.
        Lancet. 2008; 371: 1050-1052
        • Lövey K.
        • Fodor J.
        • Major T.
        • et al.
        Fat necrosis after partial-breast irradiation with brachytherapy or electron irradiation versus standard whole-breast radiotherapy-4-year results of a randomized trial.
        Int J Radiat Oncol Biol Phys. 2007; 69: 724-731
        • De Vathaire F.
        • Hawkins M.
        • Campbell S.
        • et al.
        Second malignant neoplasms after a first cancer in childhood: temporal pattern of risk according to type of treatment.
        Br J Cancer. 1999; 79: 1884-1893
        • Menu-Branthomme
        • Rubino C.
        • Shamsaldin A.
        • et al.
        Radiation dose, chemotherapy and risk of soft tissue sarcoma after solid tumours during childhood.
        Int J Cancer. 2004; 110: 87-93
        • Guerin S.
        • Guibout C.
        • Shamsaldin A.
        • et al.
        Concomitant chemo-radiotherapy and local dose of radiation as risk factors for second malignant neoplasms after solid cancer in childhood: a case-control study.
        Int J Cancer. 2007; 120: 96-102
        • Nguyen F.
        • Rubino C.
        • Guerin S.
        • et al.
        Risk of second malignant neoplasm after cancer in childhood treated with radiotherapy: correlation with the integral dose restricted to the irradiated fields.
        Int J Radiat Oncol Biol Phys. 2008; 70: 908-915
        • Sandeep T.C.
        • Strachan M.W.
        • Reynolds R.M.
        • et al.
        Second primary cancers in thyroid cancer patients: a multinational record linkage study.
        J Clin Endocrinal Metab. 2006; 91: 1819-1825
        • Rubino C.
        • de Vathaire F.
        • Dottorini M.E.
        • et al.
        Second primary malignancies in thyroid cancer patients.
        Br J Cancer. 2003; 89: 1638-1644
        • Sagstuen H.
        • Aass N.
        • Fosså S.D.
        • et al.
        Blood pressure and body mass index in long-term survivors of testicular cancer.
        J Clin Oncol. 2005; 23: 4980-4990
      6. Curtis RE, Freedman DM, Ron E, et al. New malignancies among cancer survivors: SEER Cancer Registries, 1973–2000. National Cancer Institute, NIH Publ No. 05-5302, Bethesda, MD; 2006.

        • Nord C.
        • Ganz P.A.
        • Aziz N.
        • et al.
        Follow-up of long-term cancer survivors in the Nordic countries.
        Acta Oncol. 2007; 46: 433-440